Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Details

Serval ID
serval:BIB_E585E8F98667
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".
Journal
Lancet
Author(s)
Gavras H., Biollaz J., Waeber B., Brunner H.R., Gavras I., Davies R.O.
ISSN
0140-6736
Publication state
Published
Issued date
1981
Peer-reviewed
Oui
Volume
2
Number
8246
Pages
543-547
Language
english
Abstract
The effects of the new oral converting enzyme inhibitor "MK-421" on blood pressure, plasma renin activity, plasma angiotensin II, aldosterone, and angiotensin converting enzyme were assessed in 16 hypertensive patients. Maximum (maintenance) doses ranged from 2.5 mg-40 mg daily. Blood pressure decreased from 177 +/- 7/111 +/- 4 mm Hg to 145 +/- 6/94 +/- 3 mm Hg supine and from 174 +/- 7/177 +/- 4 mm Hg to 142 +/- 6/101 +/- 3 mm Hg upright (mean +/- SEM, p less than 0.001 for both). Heart rate did not change significantly. Plasma renin activity rose during treatment, whereas plasma angiotensin II, aldosterone, and angiotensin converting enzyme remained suppressed at 24h after the maximum dose. Magnitude of blood pressure reduction after the maximum dose did not correlate with baseline plasma renin activity levels. No side-effects were noted during the 2-10 week observation period. MK-421 is similar to its predecessors in efficacy and clinical and biochemical correlates, the main difference being its higher potency and longer duration of action.
Keywords
Administration, Oral, Adult, Aged, Aldosterone, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Dipeptides, Double-Blind Method, Drug Evaluation, Enalapril, Female, Humans, Hypertension, Male, Middle Aged, Renin
Pubmed
Web of science
Create date
25/01/2008 10:41
Last modification date
20/08/2019 16:08
Usage data